Cardioxane (dexrazoxane) - Important Safety Information from Novartis as approved by the Irish Medicines Board 03.08.2010

Notice type: 3rd Party Publications

Date: 03/08/2010

 

Problem Or Issue:
Important Safety Information communication from Novartis on the association of Cardioxane with an increased risk of secondary malignancies in children.

Important Safety Information - Cardioxane (dexrazoxane)



« Back